AstraZeneca shares recorded their biggest one-day drop since March 2020 on Tuesday following a report that dozens of senior ...

AstraZeneca Plc shares plunged in London, erasing about £14 billion ($18 billion) of market value, amid escalating concerns ...

An insurance fraud investigation linked to AstraZeneca (AZN) expands in China involving dozens of senior executives. Read ...

AstraZeneca PLC shed £15 billion in market capitalization on Tuesday, after investors were underwhelmed by early data from a ...

Europe's STOXX 600 eked out minor gains on Tuesday led by gains in industrials as investors assessed a slew of downbeat ...

Key Takeaways AstraZeneca shares declined Tuesday after reports that senior executives in China were potentially implicated ...

AstraZeneca's (NASDAQ:AZN) selloff on Tuesday in response to reports that the company is facing a fraud investigation in ...

An investigation involving the drugmaker’s China president is the latest industry crackdown to trigger uncertainty about ...

The head of multinational pharmaceutical giant AstraZeneca's China arm is under investigation in the country, the firm said.

Chinese authorities detained AstraZeneca employees amid a probe into data privacy breaches and unlicensed drug sales, stock ...

AstraZeneca’s stock price dropped by 8.4% during Tuesday’s trading in London after a report fueled fears of a potentially ...

Analyst Etzer Darout of BMO Capital maintained a Buy rating on AstraZeneca (AZN – Research Report), retaining the price target of $89.00.